JP6663350B2 - ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 - Google Patents

ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 Download PDF

Info

Publication number
JP6663350B2
JP6663350B2 JP2016546835A JP2016546835A JP6663350B2 JP 6663350 B2 JP6663350 B2 JP 6663350B2 JP 2016546835 A JP2016546835 A JP 2016546835A JP 2016546835 A JP2016546835 A JP 2016546835A JP 6663350 B2 JP6663350 B2 JP 6663350B2
Authority
JP
Japan
Prior art keywords
loh
cancer
brca
pharmaceutical composition
genomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016546835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504623A5 (enExample
JP2017504623A (ja
Inventor
リン，ケヴィン
Original Assignee
クロヴィス・オンコロジー，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロヴィス・オンコロジー，インコーポレーテッド filed Critical クロヴィス・オンコロジー，インコーポレーテッド
Publication of JP2017504623A publication Critical patent/JP2017504623A/ja
Publication of JP2017504623A5 publication Critical patent/JP2017504623A5/ja
Application granted granted Critical
Publication of JP6663350B2 publication Critical patent/JP6663350B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016546835A 2014-01-16 2015-01-14 ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 Expired - Fee Related JP6663350B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461928326P 2014-01-16 2014-01-16
US61/928,326 2014-01-16
US201462004424P 2014-05-29 2014-05-29
US62/004,424 2014-05-29
US201462039516P 2014-08-20 2014-08-20
US62/039,516 2014-08-20
US201462076165P 2014-11-06 2014-11-06
US62/076,165 2014-11-06
PCT/US2015/011413 WO2015108986A1 (en) 2014-01-16 2015-01-14 Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Publications (3)

Publication Number Publication Date
JP2017504623A JP2017504623A (ja) 2017-02-09
JP2017504623A5 JP2017504623A5 (enExample) 2018-02-22
JP6663350B2 true JP6663350B2 (ja) 2020-03-11

Family

ID=53543398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546835A Expired - Fee Related JP6663350B2 (ja) 2014-01-16 2015-01-14 ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用

Country Status (5)

Country Link
US (1) US20180163271A1 (enExample)
EP (1) EP3094752A4 (enExample)
JP (1) JP6663350B2 (enExample)
CN (1) CN105917007A (enExample)
WO (1) WO2015108986A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CA2839210A1 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
EP3660161B1 (en) 2011-12-21 2024-07-31 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP3415915B1 (en) 2012-02-23 2024-10-23 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
US20160160294A1 (en) * 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
JP6763114B2 (ja) * 2016-06-02 2020-09-30 国立大学法人 琉球大学 オオフトモモ抽出物を含むｐａｒｐ阻害剤
EP3478286B1 (en) * 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
TWI879716B (zh) * 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
PL3688155T3 (pl) * 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
JP2021501203A (ja) * 2017-10-30 2021-01-14 アプトース バイオサイエンシズ インコーポレイテッド がん治療用のアリールイミダゾール
EP3703669B1 (en) * 2017-11-01 2025-08-06 Dana-Farber Cancer Institute, Inc. Usp1 or uaf1 inhibitors for use in treating cancer
WO2019099736A1 (en) * 2017-11-15 2019-05-23 The Regents Of The University Of California Methods of treating extrachromosomal dna expressing cancers
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019195443A1 (en) * 2018-04-04 2019-10-10 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
WO2020163170A1 (en) * 2019-02-05 2020-08-13 The Board Of Regents Of The University Of Texas System Trapping-free parp inhibitors
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
WO2025078404A1 (en) * 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair
CN118995870B (zh) * 2024-06-27 2025-05-27 华中科技大学同济医学院附属同济医院 PARP抑制剂Veliparib在筛除BRCA1杂合突变胚胎中的应用和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
WO2011160063A2 (en) * 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2704303T3 (es) * 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
US8729048B2 (en) * 2011-11-22 2014-05-20 Mayo Foundation For Medical Education And Research Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents
AU2012342562B2 (en) * 2011-11-25 2017-02-23 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
EP3660161B1 (en) * 2011-12-21 2024-07-31 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP3415915B1 (en) * 2012-02-23 2024-10-23 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
CA2867434C (en) * 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

Also Published As

Publication number Publication date
JP2017504623A (ja) 2017-02-09
EP3094752A4 (en) 2017-08-16
WO2015108986A1 (en) 2015-07-23
US20180163271A1 (en) 2018-06-14
EP3094752A1 (en) 2016-11-23
CN105917007A (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
JP6663350B2 (ja) ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
Jiang et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
Spiteri et al. Evolutionary dynamics of residual disease in human glioblastoma
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
Park et al. Molecular testing of brain tumor
Na et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
ES2862331T3 (es) Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer
ES2764423T3 (es) Método para determinar el estado mutacional de PIK3CA en una muestra
ES2909899T3 (es) Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
Farah et al. Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation
Huss et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p. D419del)
Helena et al. Germline EGFR T790M mutation found in multiple members of a familial cohort
JP6709541B2 (ja) 大腸癌に対する薬物療法の感受性を予測する方法
EP3766986A1 (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
Takeda et al. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy
WO2016095093A1 (zh) 肿瘤筛查方法、目标区域变异检测方法和装置
Liao et al. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
Roura et al. Identification of the immune gene expression signature associated with recurrence of high-grade gliomas
Kim et al. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues
Kim et al. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
Kotliarov et al. Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes
Deycmar et al. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques
de Siqueira et al. Targeted next-generation sequencing of glandular odontogenic cyst: a preliminary study
JP2023542273A (ja) Ａｍｌを処置するための治療、ならびにｒａｒａアゴニスト、低メチル化剤、およびｂｃｌ－２阻害剤の使用
Barry et al. DNA methylation levels at chromosome 8q24 in peripheral blood are associated with 8q24 cancer susceptibility loci

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200214

R150 Certificate of patent or registration of utility model

Ref document number: 6663350

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees